IHS 340 B Cell Development & Immunity

B Cell Development & Isotype Switching

  • B Cell Activation Processes: Includes proliferation, somatic hypermutation, and isotype switching driven by CD4 T follicular helper (Tfh) cells, particularly influenced by IL-21 and other cytokines like IL-4, IL-5, and IL-13.

  • Allergic Responses: Allergies result from Th2 cell responses promoting IgE production, a key player in initiating hypersensitivity reactions.

Hematopoiesis

  • Source of Immune Cells: The bone marrow produces various white blood cells such as B cells, T cells, and innate lymphoid cells (ILCs) essential for immunity.

Innate Lymphoid Cells (ILCs)

  • Types of ILCs: ILC1, ILC2, and ILC3, each producing distinct cytokines impacting immune responses.

  • Function: Act as early sources of polarizing cytokines and shape the immune response to environmental cues and pathogens.

Activation of Mast Cells

  • Mast Cells and IgE: Mast cells express FcεRI (high-affinity IgE receptor). Activation leads to degranulation and release of mediators such as histamine, leukotrienes, and prostaglandins, contributing to allergic reactions.

  • Allergic Reaction Phases: Immediate reactions involve vascular responses within minutes; late-phase includes leukocyte recruitment and inflammation over hours to days.

Allergic Pathophysiology**

  • Airway Responses in Allergies: Allergens can damage tissues, triggering mucus production and bronchoconstriction leading to symptoms in asthma and other allergic diseases.

  • Epithelial Damage: Enzymatic activity from allergens can heighten the allergic response by activating immune pathways, notably through molecules like IL-33 which modulates dendritic cell activity.

Therapeutic Approaches**

  • Monoclonal Antibodies: Treatments like Dupilumab target IL-4 signaling to mitigate allergic responses.

  • Allergy Shots: Immunotherapy involving regular exposure to allergens to build tolerance over time and reduce IgE production.

  • Antihistamines and Corticosteroids: Used to mitigate allergic symptoms by blocking histamine receptors or suppressing inflammatory responses, respectively.

Prostaglandins & Leukotrienes

  • Role in Inflammation: Derived from arachidonic acid, these mediators play a crucial role in pain, inflammation, and orchestrating immune responses. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of these mediators to alleviate symptoms.

The Atopic March**

  • Progression of Allergies: Describes how the development of one allergic condition increases susceptibility to others, beginning typically with atopic dermatitis, leading to food allergies, asthma, and allergic rhinitis in children.

B Cell Development & Isotype Switching

B Cell Activation Processes:

  • Involves several key processes including proliferation, somatic hypermutation, and isotype switching.

  • These processes are driven primarily by CD4 T follicular helper (Tfh) cells, which provide crucial signals for B cell activation.

  • Key cytokines influencing these processes include IL-21, which promotes B cell survival and differentiation; IL-4, IL-5, and IL-13 which are critical for class switching and the production of specific antibody isotypes such as IgE.

Allergic Responses:

  • Allergies are primarily a result of T helper 2 (Th2) cell responses that lead to the overproduction of IgE antibodies.

  • IgE binds to allergens and triggers mast cell degranulation, leading to the release of mediators responsible for hypersensitivity reactions. These reactions can range from mild to life-threatening anaphylactic responses, depending on the individual and the context of exposure.

Hematopoiesis

Source of Immune Cells:

  • The bone marrow is a critical site for hematopoiesis, the process through which all blood cells, including various white blood cells such as B cells, T cells, and innate lymphoid cells (ILCs), are produced.

  • Hematopoietic stem cells (HSCs) in the bone marrow give rise to these immune cells, which play essential roles in both adaptive and innate immunity.

Innate Lymphoid Cells (ILCs)

Types of ILCs:

  • ILCs are categorized into three main types: ILC1, ILC2, and ILC3, each characterized by their cytokine production patterns.

  • ILC1 cells produce cytokines such as interferon-γ (IFN-γ) that activate macrophages, while ILC2 cells produce cytokines like IL-4, IL-5, and IL-13, which are important in orchestrating allergic responses. ILC3 cells produce IL-17 and IL-22, playing vital roles in maintaining mucosal immunity.

Function:

  • ILCs act as crucial early sources of polarizing cytokines in response to environmental cues, thereby shaping the immune response to various pathogens and influencing the development of both local and systemic immune responses.

Activation of Mast Cells

Mast Cells and IgE:

  • Mast cells are equipped with high-affinity IgE receptors (FcεRI). Upon activation through cross-linking of IgE by allergens, mast cells undergo degranulation, releasing a variety of mediators, including histamine, leukotrienes, and prostaglandins.

  • These mediators contribute to the characteristic features of allergic reactions, such as vasodilation, increased vascular permeability, and bronchoconstriction.

Allergic Reaction Phases:

  • Allergic reactions can be divided into two phases: an immediate hypersensitivity reaction occurring within minutes, driven by pre-formed mediators, and a late-phase reaction that involves the recruitment of leukocytes and the release of additional inflammatory mediators over hours to days.

Allergic Pathophysiology

Airway Responses in Allergies:

  • Allergens can cause significant tissue damage, triggering a cascade of immune responses that result in mucus production, airway hyperreactivity, and bronchoconstriction, which manifest as symptoms of asthma and other allergic diseases.

  • This can lead to chronic airway inflammation and remodeling, complicating disease management.

Epithelial Damage:

  • Enzymatic activity from allergens, such as proteases, can further exacerbate the allergic response by activating immune pathways that involve innate immune cells and can sensitize dendritic cells through factors like IL-33, enhancing Th2 responses.

Therapeutic Approaches

Monoclonal Antibodies:

  • Modern treatments, such as Dupilumab, target IL-4 signaling pathways, effectively mitigating various allergic responses by blocking receptor interactions that lead to IgE production and airway inflammation.

  • Other monoclonal antibodies focus on different parts of the IgE lifecycle or target Th2 cytokines directly.

Allergy Shots:

  • Immunotherapy, commonly known as allergy shots, involves the gradual introduction of allergens to the immune system in controlled doses, aimed at building long-lasting tolerance.

  • This method reduces the overall production of IgE and the severity of allergic reactions over time.

Antihistamines and Corticosteroids:

  • Antihistamines work by blocking histamine receptors to alleviate symptoms such as itching, sneezing, and congestion.

  • Corticosteroids serve to suppress the overall inflammatory response, reducing swelling and irritation in response to allergens.

Prostaglandins & Leukotrienes

Role in Inflammation:

  • Prostaglandins and leukotrienes are mediators derived from arachidonic acid that play pivotal roles in inflammation and pain signaling.

  • Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymes responsible for their production, thereby alleviating pain and inflammation associated with various conditions, including allergic reactions.

The Atopic March

Progression of Allergies:

  • The atopic march describes the sequential development of allergic conditions in children, often beginning with atopic dermatitis, which predisposes individuals to subsequent food allergies, bronchial asthma, and allergic rhinitis.

  • Understanding this progression is essential for early intervention and management to prevent the progression or exacerbation of allergic diseases.